Related Experiment Video
Updated: Oct 5, 2025
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
12.1K
High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
1Endocrinology Service, Department of General Medicine, Sengkang General Hospital, 110 Sengkang East Way, Singapore 544886, Singapore.
Clinics and Practice
|January 25, 2022
Summary
High-dose liraglutide combined with SGLT2 inhibitors shows remarkable efficacy for type 2 diabetes and obesity. This combination therapy offers significant benefits in glycemic control and weight loss.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists are key treatments for Type 2 diabetes mellitus (DM).
- These drug classes offer glucose-lowering, weight management, and cardioprotective/reno-protective benefits.
- High-dose liraglutide (3 mg daily) is an effective obesity treatment, with or without DM.
Observation:
- Two patients exhibited unusual, rapid improvements in glycemic control and weight loss when treated with a combination of high-dose liraglutide and an SGLT2 inhibitor.
- These responses suggest a synergistic effect between the two therapeutic classes.
Findings:
- Combination therapy with high-dose liraglutide and SGLT2 inhibitors demonstrates marked and rapid improvements in glycemic control.
- Significant weight loss was observed in patients receiving this combined treatment regimen.
- The study highlights complementary mechanisms of action between GLP-1 agonists and SGLT2 inhibitors.
Implications:
- This combination therapy offers a potent strategy for managing Type 2 diabetes and obesity.
- Clinical pearls are provided for physicians utilizing this combined treatment.
- The findings are timely given the concurrent epidemics of obesity and COVID-19.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
461
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
461
01:23Dipeptidyl Peptidase 4 Inhibitors
280
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
280
01:06Oral Hypoglycemic Agents: Glinides
290
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
290
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
328
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
328
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
306
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
306
01:16Insulin: Dosing Regimen and Adverse Effects
294
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
294